Obagi Medical Products (OMPI) Discontinues Distribution in the Pharmacy Channel
Up)
Obagi Medical Products, Inc. (NASDAQ: OMPI) announced that it has ceased selling SoluCLENZ Rx Gel(TM) which had been sold through pharmacies since August 2008.
"Our patented solubilized benzoyl peroxide (BPO) technology that is in our acne product lines has been shown to provide an enhanced efficacy profile compared to the leading BPO/antibiotic combination acne product in more than 15 clinical studies and publications. This novel BPO technology has drawn the interest and product adoption of key opinion leaders and top acne prescribing dermatologists as evidenced by the success of the Obagi CLENZIderm(R) M.D. brand in the physician-dispense channel," said Steve Carlson, President and CEO.
"Our patented solubilized benzoyl peroxide (BPO) technology that is in our acne product lines has been shown to provide an enhanced efficacy profile compared to the leading BPO/antibiotic combination acne product in more than 15 clinical studies and publications. This novel BPO technology has drawn the interest and product adoption of key opinion leaders and top acne prescribing dermatologists as evidenced by the success of the Obagi CLENZIderm(R) M.D. brand in the physician-dispense channel," said Steve Carlson, President and CEO.
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Facebook (FB) Debuts New Camera App, Will Compete with Instagram
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
